Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-26-332750
Filing Date
2026-08-04
Accepted
2026-08-04 16:04:35
Documents
76
Period of Report
2026-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q sndx-20260630.htm   iXBRL 10-Q 2373442
2 EX-10.2 sndx-ex10_2.htm EX-10.2 93608
3 EX-10.3 sndx-ex10_3.htm EX-10.3 52490
4 EX-10.4 sndx-ex10_4.htm EX-10.4 58902
5 EX-31.1 sndx-ex31_1.htm EX-31.1 15396
6 EX-31.2 sndx-ex31_2.htm EX-31.2 15956
7 EX-32.1 sndx-ex32_1.htm EX-32.1 16140
  Complete submission text file 0001193125-26-332750.txt   9127423

Data Files

Seq Description Document Type Size
8 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT sndx-20260630.xsd EX-101.SCH 950023
80 EXTRACTED XBRL INSTANCE DOCUMENT sndx-20260630_htm.xml XML 1666356
Mailing Address 730 THIRD AVENUE 9TH FLOOR NEW YORK NY 10017
Business Address 730 THIRD AVENUE 9TH FLOOR NEW YORK NY 10017 781-419-1400
Syndax Pharmaceuticals Inc (Filer) CIK: 0001395937 (see all company filings)

EIN.: 320162505 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37708 | Film No.: 261238463
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)